PicoLO™ Picosecond Nd:YAG Laser Receives FDA 510(k) Clearance for Use in Dermatology, General and Plastic Surgery

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

LASEROPTEK Co., Ltd. has announced its PicoLO picosecond Nd:YAG laser recently received U.S. Food and Drug Administration 510(k) clearance for use in Dermatology and General and Plastic Surgery.  The company is a developer and manufacturer of world class laser devices for aesthetic and medical dermatology application.

The company reports that the PicoLO generates high peak power and consistent picosecond pulse duration producing the strongest photomechanical forces within the skin to quickly and effectively breakdown and fragment pigments such as those found in tattoos. In addition, PicoLO incorporates LASEROPTEK’s patented Diffractive Optical Element (DOE) fractional technology consistently creating Laser-induced Optical Breakdown (LIOB) in the dermis even at low power.

In addition the company notes the efficient combination of photomechanical effect and LIOB gives PicoLO a significant point of difference with picosecond lasers on the market and delivers numerous advantages to both patients and providers.

C.J. Lee, CEO of LASEROPTEK said, “Exceptionally stable energy output and picosecond pulse duration are key technological developments integrated into PicoLO further distancing it from the competition. High stability in both laser output and pulse duration is central to delivering consistently efficacious treatment outcomes while simultaneously minimizing patient discomfort.”

Mr. Lee concluded, “Shortly after receiving 510(k) clearance for our LOTUS IIITM, multi-pulsed Er:YAG laser at the end of 2018, the PicoLO clearance will significantly increase LaserOptek sales in the U.S. market. Both LOTUS III and PicoLO are well received in multiple international markets and we are now in the process of establishing an exclusive, full-service dealer network in North America. I encourage anyone who sells, services and provides clinical education to the aesthetic and medical dermatology and plastic surgery markets to contact us as soon as possible. PicoLO’s technology-rich DNA in combination with LASEROPTEK’s world class technical and clinical support will garner the attention of dealers, physicians and patients.”



Subscribe to Medical Device News Magazine here.

Related Articles